Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
This large-scale analysis found a consistent, robust reduction in LDL-C with alirocumab across a wide range of ages regardless of hypertension or smoking status.
Maternal obesity and gestational diabetes may have important effects on early child body composition, but likely do not directly affect left ventricular mass in offspring.
Results from a phase 3 trial evaluating the efficacy of evinacumab in the treatment of patients with HoFH showed that the investigational ANGPTL3 antibody reduced LDL-C by 49%.
Increased variations of body mass index and high-density lipoprotein cholesterol during childhood are independent risk factors for the development of diabetes.
The Endocrine Society published a clinical practice guideline cosponsored by the American Diabetes Association and the European Society of Endocrinology regarding the primary prevention of ASCVD and T2D.
